.avif)
.avif)
Boehringer Ingelheim Email Format
Pharmaceutical Manufacturing
・
50,001-100,000 employees
・
Ingelheim am Rhein, Germany
Boehringer Ingelheim is a global pharmaceutical company that researches, develops, and manufactures innovative medicines and therapies for human and animal health.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
first.last@boehringer-ingelheim.com
Company Overview
Industry
Pharmaceutical Manufacturing
Founded
1885
Headquarters
Ingelheim am Rhein, Germany
Revenue
$5B-$10B
FUNDING Stage
Family-Owned
Key Executives
Shashank Deshpande (Chairman of the Board of Managing Directors), Frank Hubler (Member of the Board of Managing Directors with responsibility for Finance), Harsha Deshmukh (Member of the Board of Managing Directors with responsibility for IT and Global Business Services)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Boehringer Ingelheim?
Boehringer Ingelheim uses the first.last format on boehringer-ingelheim.com, so Jane Smith would be jane.smith@boehringer-ingelheim.com.
What are the main therapeutic areas Boehringer Ingelheim focuses on in human health research?
Boehringer Ingelheim concentrates its human health research on cardio-renal-metabolic diseases, central nervous system disorders, oncology, immunology, and respiratory diseases, with products like Jardiance and Pradaxa among its best-known treatments in these areas.
How large is Boehringer Ingelheim as a company?
Boehringer Ingelheim employs approximately 46,666 people globally and is headquartered in Ingelheim am Rhein, Germany. You can use Clay to enrich a prospect list with specific contacts across the company's international offices.
Who leads Boehringer Ingelheim's Animal Health business unit?
Shashank Deshpande, Chairman of the Board of Managing Directors, previously held direct responsibility for Boehringer Ingelheim's Animal Health Business Unit before taking on the Human Pharma Business Unit in 2025. The Animal Health division covers companion animals and livestock with products including NexGard and Vetmedin.
Does Boehringer Ingelheim's Jardiance treat conditions beyond type 2 diabetes?
Yes, Jardiance, Boehringer Ingelheim's empagliflozin-based medicine, is also FDA-approved to reduce the risk of cardiovascular death and hospitalization in adults with heart failure, and it carries an indication for chronic kidney disease as well.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating